Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 96.48% is in line with its 5-year average of 96.52%, around the middle of its 5-year range (95.00%–97.23%).
0.02% below its 12-month average of 96.50%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-07-03): 96.71%.
GROSS MARGIN
96.48%
GROSS MARGIN AVG TTM
96.50%
GROSS MARGIN AVG 3Y
96.33%
GROSS MARGIN AVG 5Y
96.52%
GROSS MARGIN AVG 10Y
96.53%
GROSS MARGIN AVG 15Y
96.31%
GROSS MARGIN AVG 20Y
96.94%
CURRENT VS TTM AVG
-0.02%
CURRENT VS 3Y AVG
+0.15%
CURRENT VS 5Y AVG
-0.04%
CURRENT VS 10Y AVG
-0.05%
CURRENT VS 15Y AVG
+0.17%
CURRENT VS 20Y AVG
-0.47%
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+134.15%
vs the sector median at left
Market Cap
$14.69B
Gross Margin
32.24%
TTM Avg
31.70%
3Y Avg
34.15%
5Y Avg
35.17%
Market Cap
$14.63B
Gross Margin
97.97%
TTM Avg
98.37%
3Y Avg
98.27%
5Y Avg
98.48%
Market Cap
$14.54B
Gross Margin
84.67%
TTM Avg
88.63%
3Y Avg
87.78%
5Y Avg
88.43%
Market Cap
$15.07B
Gross Margin
54.69%
TTM Avg
54.56%
3Y Avg
56.03%
5Y Avg
57.27%
Market Cap
$14.04B
Gross Margin
90.18%
TTM Avg
86.45%
3Y Avg
83.14%
5Y Avg
81.21%
Market Cap
$13.81B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$13.11B
Gross Margin
93.35%
TTM Avg
96.31%
3Y Avg
90.48%
5Y Avg
92.91%
Market Cap
$13.01B
Gross Margin
78.18%
TTM Avg
81.22%
3Y Avg
79.53%
5Y Avg
80.59%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exelixis, Inc. (EXEL) | $14.66B | 96.48% | 96.50% | 96.33% | 96.52% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | 32.24% | 31.70% | 34.15% | 35.17% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 97.97% | 98.37% | 98.27% | 98.48% |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.54B | 84.67% | 88.63% | 87.78% | 88.43% |
| Solventum Corporation (SOLV)vs › | $15.07B | 54.69% | 54.56% | 56.03% | 57.27% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 90.18% | 86.45% | 83.14% | 81.21% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | 0.00% | 0.00% | 25.00% | 50.00% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | 93.35% | 96.31% | 90.48% | 92.91% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 78.18% | 81.22% | 79.53% | 80.59% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 98.30% | 98.34% | 98.50% | 98.50% |
Gross Margin
96.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-07-03 | 96.71% |
| 2026-04-03 | 96.73% |
| 2026-01-02 | 95.58% |
| 2025-10-03 | 96.89% |
| 2025-07-04 | 96.57% |
| 2025-04-04 | 96.55% |
| 2024-12-31 | 96.48% |
| 2024-09-27 | 96.79% |
| 2024-06-28 | 97.23% |
| 2024-03-29 | 95.00% |
| 2023-12-31 | 95.46% |
| 2023-09-29 | 96.02% |
| 2023-06-30 | 96.23% |
| 2023-03-31 | 96.50% |
| 2022-12-31 | 96.24% |
| 2022-09-30 | 96.28% |
| 2022-07-01 | 96.79% |
| 2022-04-01 | 96.29% |
| 2021-12-31 | 97.14% |
| 2021-10-01 | 96.38% |
| 2021-07-02 | 96.14% |
| 2021-04-02 | 95.12% |
| 2020-12-31 | 96.65% |
| 2020-10-02 | 96.22% |
| 2020-07-03 | 96.45% |
| 2020-04-03 | 95.91% |
| 2019-12-31 | 95.62% |
| 2019-09-27 | 97.23% |
| 2019-06-28 | 96.86% |
| 2019-03-29 | 96.52% |
| 2018-12-31 | 96.78% |
| 2018-09-28 | 96.73% |
| 2018-06-29 | 96.78% |
| 2018-03-30 | 97.34% |
| 2017-12-31 | 96.51% |
| 2017-09-29 | 96.95% |
| 2017-06-30 | 96.96% |
| 2017-03-31 | 96.04% |
| 2016-12-31 | 97.61% |
| 2016-09-30 | 96.05% |
| 2016-07-01 | 95.70% |
| 2016-04-01 | 95.56% |
| 2015-12-31 | 89.71% |
| 2015-10-02 | 85.59% |
| 2015-07-03 | 91.42% |
| 2015-04-03 | 91.84% |
| 2014-12-31 | 90.70% |
| 2014-09-26 | 90.89% |
| 2014-06-27 | 92.73% |
| 2014-03-28 | 93.70% |
| 2013-12-31 | 93.95% |
| 2013-09-27 | 94.69% |
| 2013-06-28 | 97.60% |
| 2013-03-29 | 97.10% |
| 2012-12-31 | 100.00% |
| 2012-09-30 | 100.00% |
| 2012-06-29 | 100.00% |
| 2012-03-30 | 100.00% |
| 2011-12-31 | 100.00% |
| 2011-09-30 | 100.00% |
| 2011-07-01 | 100.00% |
| 2011-04-01 | 100.00% |
| 2010-12-31 | 100.00% |
| 2010-10-01 | 100.00% |
| 2010-07-02 | 100.00% |
| 2010-04-02 | 100.00% |
| 2009-12-31 | 100.00% |
| 2009-10-02 | 94.61% |
| 2009-07-03 | 94.02% |
| 2009-04-03 | 92.90% |
| 2008-12-31 | 100.00% |
| 2008-09-26 | 100.00% |
| 2008-06-27 | 100.00% |
| 2008-03-28 | 100.00% |
| 2007-12-31 | 99.31% |
| 2007-09-28 | 99.81% |
| 2007-06-29 | 99.75% |
| 2007-03-30 | 99.74% |
| 2006-12-31 | 328.68% |
| 2006-09-30 | 100.00% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 98.50% |
| 2005-12-31 | 520.80% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | 100.00% |
| 2004-12-31 | 330.78% |
| 2004-09-30 | 100.00% |
| 2004-06-30 | 100.00% |
| 2004-03-31 | 100.00% |
| 2003-12-31 | 100.00% |
| 2003-09-30 | 100.00% |
| 2003-06-30 | 100.00% |
| 2003-03-31 | 100.00% |
| 2002-12-31 | 100.00% |
| 2002-09-30 | 100.00% |
